Skip to content

Researchers have validated an EEG test to diagnose the severity of schizophrenia.

Researchers at University of California have validated an EEG test to study and treat schizophrenia. The findings, published in two separate studies, offer a clinical test that could be used to help diagnose persons at risk for developing mental illness later in life, as well as an approach for measuring the efficacies of different treatment options.

One of the studies, reported in Schizophrenia Research, shows that schizophrenia patients don’t register subtle changes in reoccurring sounds as well as others and that this deficit can be measured by recording patterns of electrical brain activity obtained through electroencephalography (EEG).

The second study, published in NeuroImage: Clinical, establishes a link between certain EEG tests and patients’ cognitive and neurosocial impairments, suggesting that the EEG test could be used to objectively measure the severity of a patient’s condition, and conversely that it might be possible to alleviate some of the symptoms of schizophrenia with specialized cognitive exercises designed to strengthen auditory processing.

The team are at the point where they can begin to bring simple EEG tests into the clinical setting to help patients. The researchers think it may be possible to train some patients’ auditory circuits to function better. This could improve their quality of life, and possibly reduce common symptoms of schizophrenia such as hearing voices.

In experiments, UC San Diego scientists and colleagues with the Consortium on the Genetics of Schizophrenia monitored volunteers’ electrical brain activity patterns as they listened to a sequence of beeps that occasionally included a discordant prolonged beep. The lengthier beeps were one-twentieth of a second longer than the standard beeps and occurred roughly 10 percent of the time.

A total of 1,790 people were tested at five sites nationwide as part of a National Institutes of Health-funded study to unravel the genetic basis of schizophrenia. Nine-hundred and sixty-six were schizophrenia patients; 824 were healthy control subjects.

The EEG data were analyzed for two auditory processing metrics. One is known as mismatch negativity (MMN). Measured in microvolts, MMN represents the difference between the brain’s response to the expected stream of beeps and its response to the singular, different ping. The other, called P3a, is a measure of the electrical energy emitted by the brain as it automatically shifts attention to the longer beep.

People with schizophrenia were consistently shown to have reduced MMN and P3a relative to those without the disease, suggesting they had a muted ability to detect and direct their attention to the discordant beep.

In the second study, researchers showed that measures of MMN and P3a were associated with the severity of a patient’s symptoms and their day-to-day real-world functioning.

Specifically, in a comparison of MMN and P3a measurements from 42 patients with schizophrenia and 47 non-psychiatric comparison subjects, scientists showed that differences in these auditory processing metrics accounted for approximately half of the variance in the severity of patients’ symptoms and their ability to perform tasks necessary for real-world functioning.

The two studies further validate the ability to measure MMN and P3a with only one EEG electrode placed on the front of the scalp, meaning that the EEG testing can be conducted outside of academic research laboratories.

Researchers plan to use their studies’ findings to try to improve the quality of life for patients.  The future goal is to see if the team can help people improve their brain functioning by providing daily cognitive exercises that are designed to sharpen their sensory information processing.

The researchers will then use EEGs to identify markers that predict which patients are most likely to benefit from this form of treatment.

Source:  University of California – San Diego

Grand-average deviance response waveforms for the NCS and SZ subject groups for frontocentral scalp channel Fz (highlighted in pink) and for the six contributing IC source clusters. The vertical scale for the source clusters is scalp-projected RMS µV across all scalp channels. The corresponding between-group Cohen's d effect sizes are noted (NS = non-significant) (center). The three-dimensional equivalent dipole localization plot shows the centroid locations of each IC source cluster in the MNI template brain.  Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia.  Light et al 2014.
Grand-average deviance response waveforms for the NCS and SZ subject groups for frontocentral scalp channel Fz (highlighted in pink) and for the six contributing IC source clusters. The vertical scale for the source clusters is scalp-projected RMS µV across all scalp channels. The corresponding between-group Cohen’s d effect sizes are noted (NS = non-significant) (center). The three-dimensional equivalent dipole localization plot shows the centroid locations of each IC source cluster in the MNI template brain. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. Light et al 2014.

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

2 thoughts on “Researchers have validated an EEG test to diagnose the severity of schizophrenia. Leave a comment

  1. I appreciate your details in this article. It is smart, well-written and effortless to comprehend. You have my attention on this subject. I will be back.

Leave a Reply

Translate »